NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Lung: Metastatic non-squamous NSCLC - chemo-immunotherapy

Free question published 07 November 2026

RespiratoryMetastatic non-squamous NSCLC - chemo-immunotherapy

A 61-year-old man presents with metastatic non-squamous NSCLC and liver and contralateral lung metastases. Molecular testing shows no EGFR, ALK or ROS1 alteration. The PD-L1 tumour proportion score is 15%. He has WHO performance status 1 and no contraindication to immunotherapy or pemetrexed. Which first-line systemic regimen has the strongest evidence base?

  1. ANivolumab plus ipilimumab
  2. BPembrolizumab plus pemetrexed and platinum
  3. CCarboplatin-paclitaxel chemotherapy alone
  4. DSingle-agent pembrolizumab
  5. EAtezolizumab monotherapy

Why B is correct

KEYNOTE-189 randomised previously untreated metastatic non-squamous NSCLC without EGFR/ALK alterations to pembrolizumab plus pemetrexed-platinum versus chemotherapy alone, showing a substantial overall survival benefit (HR 0.49 in the primary analysis; HR 0.60 at 5 years). With a PD-L1 TPS below 50%, the combination of chemotherapy and immunotherapy is preferred over single-agent immunotherapy.

And why the others are not

  • ANivolumab plus ipilimumab is the CheckMate 743 mesothelioma regimen, not the KEYNOTE-189 standard for non-squamous NSCLC.
  • CChemotherapy alone is inferior to adding pembrolizumab in this driver-negative non-squamous population per KEYNOTE-189.
  • DSingle-agent pembrolizumab is reserved for high PD-L1 expression (TPS at least 50%); at TPS 15% the chemo-immunotherapy combination is preferred.
  • EAtezolizumab monotherapy is an option only at high PD-L1 expression, not at a TPS of 15%.

Source KEYNOTE-189 - Pembrolizumab plus pemetrexed-platinum in metastatic non-squamous NSCLC — Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992-1998. (Primary: Gandhi L et al, N Engl J Med 2018;378:2078-2092).

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing